Home › Companies › SUTRO BIOPHARMA INC. › 2023-2024
Compiled from SEC Form N-PX filings and SUTRO BIOPHARMA INC.’s Form 8-K, filed June 10, 2024 (Item 5.07 on EDGAR). Page generated October 18, 2026.
Meeting of June 6, 2024: 5 items on SUTRO BIOPHARMA INC.’s Form 8-K, filed June 10, 2024: 5 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024 2024-2025
Explore SUTRO BIOPHARMA INC. in the interactive database Compare manager voting policies
These tallies are SUTRO BIOPHARMA INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Joseph M. Lobacki | 49,578,870 | -- | -- | 1,393,863 | 13,906,799 | 97% | Not verified | — |
| Elect Director: Daniel H. Petree | 33,386,033 | -- | -- | 17,586,700 | 13,906,799 | 65% | Not verified | — |
| 2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 | 64,598,771 | 118,896 | 161,865 | -- | -- | 99.8% | Not verified | — |
| 3. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers | 50,214,198 | 171,189 | 587,346 | -- | 13,906,799 | 99.6% | Not verified | — |
| 4. Approval of the amendment of the Company's 2018 Employee Stock Purchase Plan (the " ESPP ") to (i) increase the overall limit on the number of shares that may be issued under the ESPP throughout its ten-year term, and (ii) make certain non-substantive clari | 50,224,587 | 618,712 | 129,434 | -- | 13,906,799 | 99% | Not verified | — |
Source: SUTRO BIOPHARMA INC., Form 8-K, filed with the SEC on June 10, 2024 — read the filing on EDGAR.
Each item below shows how the 143 asset managers that disclosed a SUTRO BIOPHARMA INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
65% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: Daniel H. Petree
SUTRO BIOPHARMA INC.’s own tally for this item (“Elect Director: Daniel H. Petree”): 33,386,033 for, 17,586,700 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 65% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 50 asset managers below reported 7,895,863 for, 2,282,950 withheld, 152,276 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,983,134 | 0 | 0 | 0 | For |
| BlackRock | 2,633,809 | 0 | 0 | 0 | For |
| Fidelity | 1,338,900 | 0 | 0 | 500 | For |
| Dimensional | 0 | 0 | 0 | 792,430 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 505,154 | Withhold |
| TIAA | 434,955 | 0 | 0 | 0 | For |
| Equitable | 108,716 | 0 | 0 | 75,300 | Mixed |
| Nationwide | 941 | 0 | 0 | 164,047 | Withhold |
| Charles Schwab | 160,876 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 0 | 149,005 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 145,200 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 113,702 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 74,398 | Withhold |
| ETF Series Solutions | 0 | 0 | 71,577 | 0 | Abstain |
| Aberdeen | 0 | 0 | 0 | 69,389 | Withhold |
| Lincoln Financial | 1,702 | 0 | 0 | 52,178 | Withhold |
| GuideStone | 0 | 0 | 0 | 48,744 | Withhold |
| Russell Investments | 30,928 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 30,017 | Withhold |
| John Hancock | 0 | 0 | 27,512 | 0 | Abstain |
| Northern Trust | 0 | 0 | 0 | 27,332 | Withhold |
| Brighthouse | 0 | 0 | 0 | 25,793 | Withhold |
| Bridge Builder Trust | 24,111 | 0 | 0 | 0 | For |
| Pacific Life | 23,421 | 0 | 0 | 0 | For |
| State Street | 0 | 0 | 0 | 22,601 | Withhold |
Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.
Combines 3 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: Joseph M. Lobacki
SUTRO BIOPHARMA INC.’s own tally for this item (“Elect Director: Joseph M. Lobacki”): 49,578,870 for, 1,393,863 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 50 asset managers below reported 9,427,765 for, 883,935 withheld, 19,389 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,983,134 | 0 | 0 | 0 | For |
| BlackRock | 2,633,809 | 0 | 0 | 0 | For |
| Fidelity | 1,339,400 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 792,430 | Withhold |
| Goldman Sachs | 505,154 | 0 | 0 | 0 | For |
| TIAA | 434,955 | 0 | 0 | 0 | For |
| Equitable | 108,716 | 0 | 0 | 75,300 | Mixed |
| Nationwide | 164,988 | 0 | 0 | 0 | For |
| Charles Schwab | 160,876 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 149,005 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 145,200 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 113,702 | 0 | 0 | 0 | For |
| American Century | 74,398 | 0 | 0 | 0 | For |
| ETF Series Solutions | 71,577 | 0 | 0 | 0 | For |
| Aberdeen | 69,389 | 0 | 0 | 0 | For |
| Lincoln Financial | 51,802 | 0 | 0 | 2,078 | For |
| GuideStone | 48,744 | 0 | 0 | 0 | For |
| Russell Investments | 30,928 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 30,017 | 0 | 0 | 0 | For |
| John Hancock | 25,747 | 0 | 1,765 | 0 | Mixed |
| Northern Trust | 27,332 | 0 | 0 | 0 | For |
| Brighthouse | 12,574 | 0 | 0 | 13,219 | Mixed |
| Bridge Builder Trust | 24,111 | 0 | 0 | 0 | For |
| Pacific Life | 23,421 | 0 | 0 | 0 | For |
| State Street | 22,601 | 0 | 0 | 0 | For |
Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.
Combines 7 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To approve the amendment of our 2018 Employee Stock Purchase Plan (the "ESPP") to (i) increase the overall limit on the number of shares that may be issued under our ESPP throughout its ten-year term, and (ii) make certain non-substantive clarifying revisions.
SUTRO BIOPHARMA INC.’s own tally for this item (“4. Approval of the amendment of the Company's 2018 Employee Stock Purchase Plan (the " ESPP ") to (i) increase the overall limit on the number of shares that may be issued under the ESPP throughout its ten-year term, and”): 50,224,587 for, 618,712 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,983,134 | 0 | 0 | 0 | For |
| BlackRock | 2,633,809 | 0 | 0 | 0 | For |
| Fidelity | 1,339,400 | 0 | 0 | 0 | For |
| Dimensional | 792,430 | 0 | 0 | 0 | For |
| Goldman Sachs | 505,154 | 0 | 0 | 0 | For |
| TIAA | 434,955 | 0 | 0 | 0 | For |
| Equitable | 184,016 | 0 | 0 | 0 | For |
| Nationwide | 164,047 | 941 | 0 | 0 | For |
| Charles Schwab | 0 | 160,876 | 0 | 0 | Against |
| Columbia Threadneedle | 149,005 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 145,200 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 0 | 0 | 0 | 120,000 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 113,702 | 0 | 0 | 0 | For |
| American Century | 74,398 | 0 | 0 | 0 | For |
| ETF Series Solutions | 71,577 | 0 | 0 | 0 | For |
| Aberdeen | 69,389 | 0 | 0 | 0 | For |
| Lincoln Financial | 53,880 | 0 | 0 | 0 | For |
| GuideStone | 48,744 | 0 | 0 | 0 | For |
| Russell Investments | 0 | 30,928 | 0 | 0 | Against |
| AIG/SunAmerica | 30,017 | 0 | 0 | 0 | For |
| John Hancock | 27,512 | 0 | 0 | 0 | For |
| Northern Trust | 27,332 | 0 | 0 | 0 | For |
| Brighthouse | 12,574 | 13,219 | 0 | 0 | Mixed |
| Bridge Builder Trust | 24,111 | 0 | 0 | 0 | For |
| Pacific Life | 23,421 | 0 | 0 | 0 | For |
Fund voting reports, all 51 managers: 10,097,161 for, 233,928 against, 120,000 withheld. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Kynam Capital Management, LP | 0 | 0 | 0 | 1,892,497 | Withhold |
| Eversept Partners, LP | 1,488,828 | 0 | 0 | 0 | For |
| ALGERT GLOBAL LLC | 0 | 23,761 | 0 | 0 | Against |
| Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma | 0 | 1,372 | 0 | 0 | Against |
Institutional-manager reports, all 4 managers: 1,488,828 for, 25,133 against, 1,892,497 withheld.
Combines 6 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
SUTRO BIOPHARMA INC.’s own tally for this item (“3. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers”): 50,214,198 for, 171,189 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,983,134 | 0 | 0 | 0 | For |
| BlackRock | 2,633,809 | 0 | 0 | 0 | For |
| Fidelity | 1,339,400 | 0 | 0 | 0 | For |
| Dimensional | 792,430 | 0 | 0 | 0 | For |
| Goldman Sachs | 505,154 | 0 | 0 | 0 | For |
| TIAA | 434,955 | 0 | 0 | 0 | For |
| Equitable | 184,016 | 0 | 0 | 0 | For |
| Nationwide | 164,988 | 0 | 0 | 0 | For |
| Charles Schwab | 160,876 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 149,005 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 145,200 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 0 | 0 | 0 | 120,000 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 113,702 | 0 | 0 | 0 | For |
| American Century | 74,398 | 0 | 0 | 0 | For |
| ETF Series Solutions | 71,577 | 0 | 0 | 0 | For |
| Aberdeen | 69,389 | 0 | 0 | 0 | For |
| Lincoln Financial | 53,880 | 0 | 0 | 0 | For |
| GuideStone | 48,744 | 0 | 0 | 0 | For |
| Russell Investments | 30,928 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 30,017 | 0 | 0 | 0 | For |
| John Hancock | 27,512 | 0 | 0 | 0 | For |
| Northern Trust | 27,332 | 0 | 0 | 0 | For |
| Brighthouse | 12,574 | 0 | 13,219 | 0 | Mixed |
| Bridge Builder Trust | 24,111 | 0 | 0 | 0 | For |
| Pacific Life | 23,421 | 0 | 0 | 0 | For |
Fund voting reports, all 51 managers: 10,309,827 for, 8,043 against, 120,000 withheld, 13,219 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7,608,682 | 0 | 0 | 0 | For |
| Point72 | 5,847,686 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 4,121,208 | 0 | 0 | 0 | For |
| BlackRock | 2,305,607 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,241,629 | 0 | 0 | 0 | For |
| Kynam Capital Management, LP | 0 | 0 | 0 | 1,892,497 | Withhold |
| BAILLIE GIFFORD & CO LTD | 1,793,154 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 1,488,828 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,305,468 | 0 | 0 | 0 | For |
| Samsara BioCapital, LLC | 1,271,235 | 0 | 0 | 0 | For |
| State Street | 1,109,150 | 0 | 0 | 0 | For |
| Two Sigma | 1,071,064 | 0 | 0 | 0 | For |
| Aquilo Capital Management, LLC | 987,396 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 587,776 | 0 | 0 | 0 | For |
| PANAGORA ASSET MANAGEMENT INC | 530,478 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 481,509 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 0 | 440,369 | 0 | Abstain |
| Nuveen | 438,538 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 427,262 | 0 | 0 | 0 | For |
| Renaissance | 370,407 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 334,079 | 0 | 0 | 0 | For |
| DE Shaw | 296,983 | 0 | 0 | 0 | For |
| UBS | 275,057 | 0 | 0 | 0 | For |
| Northern Trust | 271,556 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 269,486 | 0 | 0 | 0 | For |
Institutional-manager reports, all 110 managers: 38,148,356 for, 102,693 against, 1,892,497 withheld, 440,369 abstained. Showing the 25 largest; see all in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.
SUTRO BIOPHARMA INC.’s own tally for this item (“2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 64,598,771 for, 118,896 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 10,317,705 for, 165 against, 120,000 withheld, 13,219 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,983,134 | 0 | 0 | 0 | For |
| BlackRock | 2,633,809 | 0 | 0 | 0 | For |
| Fidelity | 1,339,400 | 0 | 0 | 0 | For |
| Dimensional | 792,430 | 0 | 0 | 0 | For |
| Goldman Sachs | 505,154 | 0 | 0 | 0 | For |
| TIAA | 434,955 | 0 | 0 | 0 | For |
| Equitable | 184,016 | 0 | 0 | 0 | For |
| Nationwide | 164,988 | 0 | 0 | 0 | For |
| Charles Schwab | 160,876 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 149,005 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 145,200 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 0 | 0 | 0 | 120,000 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 113,702 | 0 | 0 | 0 | For |
| American Century | 74,398 | 0 | 0 | 0 | For |
| ETF Series Solutions | 71,577 | 0 | 0 | 0 | For |
| Aberdeen | 69,389 | 0 | 0 | 0 | For |
| Lincoln Financial | 53,880 | 0 | 0 | 0 | For |
| GuideStone | 48,744 | 0 | 0 | 0 | For |
| Russell Investments | 30,928 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 30,017 | 0 | 0 | 0 | For |
| John Hancock | 27,512 | 0 | 0 | 0 | For |
| Northern Trust | 27,332 | 0 | 0 | 0 | For |
| Brighthouse | 12,574 | 0 | 13,219 | 0 | Mixed |
| Bridge Builder Trust | 24,111 | 0 | 0 | 0 | For |
| Pacific Life | 23,421 | 0 | 0 | 0 | For |
Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 81,794,334 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.65% |
| 2 | BlackRock | 3.22% |
| 3 | Fidelity | 1.64% |
| 4 | Dimensional | 0.97% |
| 5 | Goldman Sachs | 0.62% |
| 6 | TIAA | 0.53% |
| 7 | Equitable | 0.22% |
| 8 | Nationwide | 0.20% |
| 9 | Charles Schwab | 0.20% |
| 10 | Columbia Threadneedle | 0.18% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | SUVRETTA CAPITAL MANAGEMENT, LLC | 9.30% |
| 2 | Point72 | 7.15% |
| 3 | MPM BioImpact LLC | 5.04% |
| 4 | BlackRock | 2.82% |
| 5 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.74% |
| 6 | Kynam Capital Management, LP | 2.31% |
| 7 | BAILLIE GIFFORD & CO LTD | 2.19% |
| 8 | Eversept Partners, LP | 1.82% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.60% |
| 10 | Samsara BioCapital, LLC | 1.55% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| S | 7.06% | 13G |
| Suvretta Capital Management, LLC | 7.06% | DEF14A |
| Adage Capital Partners GP, LLC | 5.46% | DEF14A |
| Vanguard Group | 4.50% | 13F |
| Integrated Core Strategies (US) LLC | 4.22% | DEF14A |
| BVF Inc. | 4.09% | DEF14A |
| Rubric Capital Management LP | 4.09% | DEF14A |
| William J. Newell | 2.11% | DEF14A |
| BlackRock | 2.06% | 13F |
| Dimensional Fund Advisors | 1.60% | 13F |
Percentages above are of 81,794,334 shares outstanding, as reported by SUTRO BIOPHARMA INC. on its Form 10-Q dated May 8, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SUTRO BIOPHARMA INC.’s 10-Q dated May 8, 2024. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.
At SUTRO BIOPHARMA INC.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 143 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 895 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — FOR was 99.6% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SUTRO BIOPHARMA INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2024.
SUTRO BIOPHARMA INC. proxy season coverage: 2023-2024 (this page) · 2024-2025.
Download data (CSV): ballot items · votes by manager · column guide.